- Details
- Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and...
|
- Details
- Piet Ost discusses the STORM trial, a randomized study comparing stereotactic body radiotherapy (SBRT) with elective nodal radiotherapy (ENRT) in oligometastatic prostate cancer patients. The trial, involving 80% PSMA-PET scanned patients, includes six months of androgen deprivation therapy in both arms. Results show significant benefits for ENRT in biochemical recurrence-free survival and locoreg...
|
- Details
- David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases....
|
- Details
- Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...
|
- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples. They highlight the advantages of EV analysis over traditional ctDNA, including the abili...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN prostate cancer guideline updates focusing on treatment-related bone loss in patients on androgen deprivation therapy (ADT). They emphasize the importance of addressing bone health due to increased fracture risk associated with ADT. The speakers outline a comprehensive approach to bone health management, including risk assessment using the FRAX...
|
- Details
- Rashid Sayyid and Zach Klaassen review the NCCN prostate cancer guideline updates regarding the prevention of symptomatic skeletal-related events in bone metastatic CRPC patients. They discuss the efficacy and safety profiles of denosumab and zoledronic acid, highlighting key clinical trials that have shaped current recommendations. The speakers emphasize the importance of considering dosing frequ...
|
- Details
- Andrea Miyahira interviews Michael Haffner about his group's study on the expression of TROP2, CEACAM5, and DLL3 in metastatic prostate cancer, published in NEJM Evidence. Dr. Haffner discusses their analysis of over 750 samples from 52 patients in a rapid autopsy cohort, examining protein expression across different molecular subtypes of castration-resistant prostate cancer. The study reveals dis...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer (mCRPC) treatment. They review the current management algorithm, emphasizing the importance of confirming castrate status and proper staging. The presentation covers treatment options for adenocarcinoma and small cell/neuroendocrine variants, highlighting the signi...
|
